(Q48126437)

English

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

scientific article published on 28 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J S Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

C Hsu

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

N J Chiang

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

C S Tsai

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

H H Tsou

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

S F Huang

6

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

L Y Bai

7

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

I C Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

H S Shiah

9

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

C L Ho

10

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

C J Yen

11

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

K D Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

C F Chiu

13

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

K M Rau

14

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

M S Yu

15

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Y Yang

16

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

R K Hsieh

17

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

J Y Chang

18

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Y S Shan

19

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Y Chao

20

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

L T Chen

21

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Taiwan Cooperative Oncology Group

22

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

publication date

28 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

26

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

943-949

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

Epidemiology of biliary tract cancers: an update

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV035

21 January 2018

Identifiers

10.1093/ANNONC/MDV035

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/25632066

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48126437&oldid=2186257168"